Bristol Myers 48 Hour Deadline Alert: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits against Bristol-Myers Squibb Company - BMY Pharmaceutical Investing
Cohen Milstein Files Class Action Complaint Against Bristol-Myers Squibb Company Pharmaceutical Investing
BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY Pharmaceutical Investing
Janssen to Showcase Progress on Respiratory Syncytial Virus Vaccine Candidate at ESWI 2021 Pharmaceutical Investing
FDA Approves Merck's KEYTRUDA® as Adjuvant Treatment for Adult and Pediatric Patients With Stage IIB or IIC Melanoma Following Complete Resection Pharmaceutical Investing
AbbVie Provides Update on RINVOQ® for the Treatment of Rheumatoid Arthritis in the U.S. Pharmaceutical Investing
Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19, with the Government of Canada Pharmaceutical Investing
Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month Pharmaceutical Investing
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia Pharmaceutical Investing
Universal Ibogaine Announces Expansion of Executive Team andGrant of Stock Options Pharmaceutical Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
